

REC Ref	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
17/LO/0584	173991	A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography	No		1			04/10/2018	10/12/2018	07/12/2018	11/12/2018	11/12/2018		11/12/2018		
18/YH/0127	239022	instantaneous wave-free ratio guided Multi vessel revascularization During percutaneous coronary intervention for acute myocardial infarction	Yes	24/12/2018	26	42	68	09/03/2018	17/10/2018	21/05/2018	12/11/2018	12/11/2018		06/12/2018		
17/LO/0797	220423	A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.	No					28/11/2016	05/10/2018	08/08/2017	17/01/2018		Sponsor dec	02/11/2018	B - Suspended by sponsor	Sponsor
															C - Closed by sponsor	
															J - Other	
16/SS/0014	187949	A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy	No		1			15/11/2016	17/10/2018	14/10/2016	18/10/2018	18/10/2018		22/11/2018	D - Sponsor Delays	Sponsor
17/LO/0457	215990	The Bio-inspired Artificial Pancreas for the Home	Yes	20/07/2018	35	60	95	06/07/2017	16/04/2018			21/05/2018			G - No patients consented	Neither
18/SW/0103	200303	A phase II prospective randomised clinical study of endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for inoperable ductal pancreatic carcinoma	No		51			26/03/2018	11/04/2018	31/05/2018	11/04/2018	01/06/2018			A - Permissions delayed/denied	Neither
17/LO/0389	221666	Psilocybin for major depression: A randomized control trial	No		79			18/07/2018	14/08/2018	18/06/2018		01/11/2018			E - Staff availability issues	NHS Provid
17/LO/0566	218514	An experimental medicine study to validate The 18 kD Translocator Protein as a novel neuroimmunodulatory target	No		25			17/03/2017	11/01/2018	19/12/2017	17/03/2017	05/02/2018			G - No patients consented	Neither
17/LO/1095	225278	Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women with polycystic ovarian syndrome	Yes	11/04/2018	39	22	61	09/06/2017	09/02/2018	04/09/2017	09/06/2017	20/03/2018		21/03/2018		
17/LO/1441	219916	SYNCOPE Education for patients during tilt-table tests	Yes	20/03/2018	26	36	62	02/08/2017	17/01/2018	12/09/2017		12/02/2018				
18/LO/1629	214262	A prospective study of tolerance comparing the current hydration regimen for the ABCO2 chemotherapy regimen versus a shorter hydration protocol	No		34				29/11/2018	13/12/2018		02/01/2019		02/01/2019		
17/SC/0090	215068	A trial using ctDNA blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patients (c-TRAK-TN)	No					23/06/2017	31/07/2018	05/07/2017					D - Sponsor Delays	Sponsor
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Yes	12/09/2018	93	124	217	04/09/2017	07/02/2018	31/01/2018	04/05/2018	11/05/2018		11/05/2018	D - Sponsor Delays	Sponsor
17/LO/1847	216867	A randomised phase II trial of Selinexor, cyclophosphamide and prednisone vs cyclophosphamide and prednisone in relapsed or refractory multiple myeloma (RRMM) patients.	Yes	20/07/2018	90	66	156	22/11/2017	14/02/2018	04/01/2018	11/03/2018	15/05/2018		20/06/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
															H - Contracting delays	
17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Who are candidates for Non-intensive Therapy.	No		136			05/02/2018	13/02/2018	06/03/2018	10/09/2017	29/06/2018		24/07/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
17/SC/0201	209172	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study.	Yes	23/05/2018	55	7	62	29/01/2018	22/03/2018	18/10/2017	07/05/2018	16/05/2018		16/05/2018		
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy	Yes	29/05/2018	30	34	64	10/07/2017	26/03/2018	21/11/2017	19/04/2018	25/04/2018		03/05/2018		
18/LO/0217	235711	INvestigational Study Into Transplantation of the Uterus (INSITU)	No		32			24/01/2018	23/04/2018	28/02/2018	25/05/2018	25/05/2018			G - No patients consented	Neither

16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.	Yes	17/12/2018	40	257	297	12/10/2017	23/02/2018	05/12/2016	08/02/2018	04/04/2018		02/10/2018	A - Permissions delayed/denied	Neither
17/LO/1918	229435	Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients with Intermittent Claudication (NESIC) compared to best available treatment? A Multicentre Randomised Controlled Study	Yes	08/03/2018	45	20	65	09/11/2017	02/01/2018	29/01/2018		16/02/2018		16/02/2018		
18/LO/0196	237129	A Study of Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion (CSII) in Adults with Type 1	No		16			10/01/2018	27/02/2018			15/03/2018			G - No patients consented	Neither
17/NE/0300	225917	A phase II, randomised, double-blind, placebo-controlled, parallel-group, multicentre study investigating the efficacy and safety of Sepranolone (UC1010) in patients with PMDD	Yes	04/07/2018	22	35	57	06/11/2017	08/05/2018	31/10/2017	30/05/2018	30/05/2018		18/06/2018		
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study.	Yes	14/11/2018	38	40	78	16/10/2017	28/08/2018	12/07/2018	29/08/2018	05/10/2018			G - No patients consented	Neither
17/EE/0368	213669	STRESS-L: SStudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	Yes	03/07/2018	37	60	97	12/10/2017	28/03/2018	10/11/2017	12/03/2018	04/05/2018		14/06/2018	G - No patients consented	Neither
17/EE/0498	239464	Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy	Yes	08/08/2018	114	35	149	28/11/2017	12/03/2018	12/03/2018	04/07/2018	04/07/2018			D - Sponsor Delays	Sponsor
18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	No		117			22/10/2017	19/01/2018	11/04/2018		16/05/2018			D - Sponsor Delays	Sponsor
															I - Rare diseases	
18/LO/0054	236047	Microneedle sensing of beta-lactam antibiotic concentrations in human interstitial fluid	Yes	30/04/2018	14	26	40	06/07/2017	21/03/2018	14/02/2018	06/07/2017	04/04/2018		04/04/2018		
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease	Yes	13/06/2018	3	41	44	23/05/2017	30/04/2018	21/08/2017	23/05/2017	03/05/2018		08/05/2018		
18/LO/0091	140718	Side-Stream Dark Field video analysis of cerebral microcirculation in patients with traumatic brain injury or a brain tumour: the effects of blood pressure and intracranial pressure	No		32			12/12/2017	12/02/2018	12/02/2018		16/03/2018			G - No patients consented	Neither
17/LO/1660	223181	Feasibility of Improving Risk Stratification in Brugada Syndrome	Yes	05/10/2018	56	0	56	28/02/2018	10/08/2018	22/11/2017	05/10/2018	05/10/2018				
17/EE/0387	231908	Maraviroc Add-On Therapy for Steatohepatitis in HIV	Yes	19/06/2018	0	49	49	30/08/2017	01/05/2018	08/03/2018	01/05/2018	01/05/2018		03/05/2018		
18/LO/0745	231612	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	No		32			05/04/2018	04/10/2018	11/07/2018	19/10/2018	05/11/2018			J - Other	Neither
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	Yes	20/07/2018	38	29	67	31/07/2017	14/05/2018	28/11/2017	31/07/2017	21/06/2018		22/06/2018		
17/LO/1245	208149	A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis	Yes	08/03/2018	25	31	56	11/09/2017	11/01/2018	10/11/2017	11/09/2017	05/02/2018				
17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies (AFFINITY)	No		14			20/09/2017	28/02/2018	11/01/2018	20/09/2017	14/03/2018			G - No patients consented	Neither
18/LO/0174	232220	SABRE- Serratus Anterior Block and catheter use in Rib fractures in the Emergency department	No		36			15/11/2017	12/06/2018	02/03/2018		18/07/2018			G - No patients consented	Neither
															J - Other	
17/LO/1693	233988	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson's Disease with motor fluctuations (iNDiGO)	No					04/10/2017	10/04/2018		04/10/2017				D - Sponsor Delays	Sponsor

17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Yes	05/02/2018	0	11	11	25/01/2018	25/01/2018	18/05/2017	25/01/2018	25/01/2018				
17/SC/0582	234404	A multicentre, open-label, long-term safety study of AR101 characterised oral desensitisation immunotherapy in subjects who participated in a prior AR101 study	Yes	07/08/2018	156	39	195	24/10/2017	24/01/2018	18/01/2018	27/06/2018	29/06/2018		12/07/2018	A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															G - No patients consented	
															H - Contracting delays	
16/LO/0680	186642	Strategy for maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17). A two-arm, phase 2/3 multicentre, open-label, randomised study evaluating safety and anti-viral effect of current anti-retroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants	No		39			08/11/2017	29/01/2018	28/07/2016	09/03/2018	09/03/2018		04/04/2018	D - Sponsor Delays	Sponsor
18/EE/0005	232671	A MULTICENTER, OPEN-LABEL STUDY TO ESTIMATE THE EFFECT SIZES OF HRCT ENDPOINTS IN RESPONSE TO GLUCOCORTICOID INDUCTION THERAPY IN SUBJECTS WITH PULMONARY SARCOIDOSIS	No		104			10/11/2017	19/07/2018	19/07/2018		31/10/2018			D - Sponsor Delays	Sponsor
															G - No patients consented	
															H - Contracting delays	
17/EE/0474	229785	The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients	Yes	10/04/2018	23	67	90	14/07/2017	10/01/2018	05/01/2018	02/02/2018	02/02/2018		20/02/2018	G - No patients consented	Neither
18/LO/0314	237195	Smart Catheter: A novel biosensor for early diagnosis of catheter associated urinary tract infection	No		14			21/02/2018	28/03/2018	06/04/2018		11/04/2018			D - Sponsor Delays	Sponsor
18/LO/0779	235161	A Randomized (1:1), Double blind, Multi center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF 0444913) or Azacitidine With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia.	No		163			18/12/2017	03/07/2018	15/06/2018		13/12/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0700	238068	A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hSPCs) in Subjects with Transfusion-Dependent $\beta$ Thalassemia.	No		143			18/12/2017	18/05/2018	02/07/2018	13/09/2018	08/10/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0270	228830	Can NIRS be used as an intra-operative monitor of spinal cord function and predict patient outcome after vascular surgery?	Yes	27/07/2018	31	70	101	06/04/2018	17/04/2018			18/05/2018			G - No patients consented	Neither
17/SC/0639	236312	A Phase 3 Open-Label, single-Arm Study to Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Haemophilia A Patients with Residual FVIII Levels 1 IU/dL Receiving Prophylactic FVIII Infusions	No		80			09/01/2018	15/01/2018	26/02/2018	22/03/2018	05/04/2018			D - Sponsor Delays	Sponsor
															G - No patients consented	
															H - Contracting delays	
18/LO/0070	238482	A Pivotal Clinical Trial of the Management of th Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System	Yes	20/09/2018	24	119	143	23/01/2018	30/04/2018	30/04/2018	10/05/2018	24/05/2018		24/05/2018	G - No patients consented	Neither
18/WS/0087	241031	Optimal duration of Cooling therapy in Mild Encephalopathy (COMET 1)	Yes	15/10/2018	7	70	77	02/05/2018	30/07/2018	18/06/2018	06/08/2018	06/08/2018		06/08/2018	G - No patients consented	Neither

18/YH/0212	237279	A phase Ib study of Itacitinib, a JAK1 inhibitor, in advanced hepatocellular carcinoma	Yes	31/12/2018	5	28	33	14/08/2018	28/11/2018	14/08/2018	28/11/2018	03/12/2018		10/12/2018			
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebocontrolled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	No		7			15/01/2018	01/05/2018	04/12/2017			08/05/2018		08/05/2018	D - Sponsor Delays	Neither
																G - No patients consented	
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Yes	18/10/2018	58	91	149	11/04/2018	22/05/2018	15/05/2018	13/07/2018	19/07/2018		26/09/2018		D - Sponsor Delays	Sponsor
																G - No patients consented	
18/LO/0170	236855	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	No		89			29/01/2018	20/09/2018	04/04/2018	11/12/2018	18/12/2018		18/12/2018		D - Sponsor Delays	Sponsor
																G - No patients consented	
18/NW/0031	230387	A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		308			12/02/2018	12/02/2018	08/02/2018			17/12/2018			D - Sponsor Delays	Sponsor
																G - No patients consented	
18/LO/0376	236553	Investigating physiological effects of weight loss on male fertility	Yes	16/05/2018	27	8	35	23/03/2018	11/04/2018	11/04/2018			08/05/2018				
18/LO/1162	242411	A Study to Evaluate the Safety and Efficacy of Staged Bilateral ExAblate Treatment of Medication Refractory Bilateral Essential Tremor	Yes	17/01/2019	35	41	76	25/04/2018	02/11/2018	17/10/2018	07/12/2018	07/12/2018					
18/EM/0153	240773	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency	No		38			16/05/2018	31/08/2018	28/08/2018	24/09/2018	08/10/2018				G - No patients consented	Neither
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	No		39			26/02/2018	04/06/2018	14/05/2018	13/07/2018	13/07/2018		31/07/2018		F - No patients seen	Neither
																I - Rare diseases	
18/LO/0235	240315	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials	No					28/02/2018	17/12/2018	17/04/2018							
18/LO/0512	196718	DICE Trial: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)	Yes	21/09/2018	79	22	101	05/03/2018	12/06/2018	05/06/2018			30/08/2018		04/09/2018	D - Sponsor Delays	Sponsor
18/NW/0109	234734	PHIL evaluation in the endovascular treatment of intracranial dural AVF	No		30			26/02/2018	12/09/2018	14/05/2018	12/09/2018	12/10/2018				G - No patients consented	Neither
18/SC/0057	230986	A prospective cross-sectional study analysing the utility of novel tablet-based audiometry and an interactive web-based hearing app as screening tools for drug-induced ototoxicity in adults with cystic fibrosis.	No		32			19/03/2018	19/03/2018	06/03/2018			20/04/2018			G - No patients consented	Neither
18/LO/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B	No		51			15/03/2018	25/07/2018	20/06/2018	04/07/2018	14/09/2018				D - Sponsor Delays	Sponsor
16/LO/2150	201093	Randomised Phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum-resistant ovarian cancer	No		150			20/03/2018	20/03/2018	26/01/2017			17/08/2018		12/09/2018	D - Sponsor Delays	Sponsor
18/SS/0010	238051	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	No		98			05/02/2018	04/05/2018	21/03/2018	01/08/2018	10/08/2018		07/09/2018		D - Sponsor Delays	Sponsor

															G - No patients consented	
															H - Contracting delays	
18/LO/0919	235977	A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation	No		39			11/04/2018	22/10/2018	29/08/2018	19/11/2018	30/11/2018			G - No patients consented	Neither
18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours	No					10/04/2018	30/07/2018	14/06/2018					Site declined to participate	
18/LO/0858	241447	A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	Yes	15/11/2018	145	38	183	13/04/2018	16/05/2018	12/07/2018		08/10/2018		08/10/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	Yes	20/11/2018	129	39	168	13/04/2018	05/06/2018	20/09/2018	09/03/2018	12/10/2018		12/10/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No		60			23/04/2018	21/06/2018	26/04/2018	07/08/2018	20/08/2018			A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															G - No patients consented	
															H - Contracting delays	
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	No		3			19/10/2017	29/10/2018		17/10/2018	01/11/2018				
18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	No		183			02/05/2018	02/05/2018	13/07/2018	13/02/2018	01/11/2018		01/11/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	No					21/09/2018	21/09/2018	19/10/2018					D - Sponsor Delays	Sponsor
18/LO/1461	245412	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)	No					06/04/2018	08/10/2018	19/10/2018					D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation: a multi-centre randomised controlled trial	No		89			10/10/2018	10/10/2018	13/02/2018		07/01/2019			D - Sponsor Delays	Sponsor
18/LO/1338	247728	PROSTAGRAM - Prostate Screening Trial using A Group of Radiological Approaches including MRI and ultrasound	Yes	16/10/2018	12	27	39	10/07/2018	07/09/2018	10/09/2018	19/09/2018	19/09/2018				
18/YH/0099	241430	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)	No		1			29/05/2018	09/08/2018	23/04/2018		10/08/2018		14/08/2018	G - No patients consented	Neither
															I - Rare diseases	

18/LO/1525	240039	Assessment of the Impact of Real-time Continuous Glucose Monitoring on People Presenting with Severe Hypoglycaemia (AIR-CGM)	No		59			31/07/2018	18/09/2018	09/11/2018		16/11/2018			D - Sponsor Delays	Sponsor
18/NE/0281	237312	Neuromuscular Electrical Stimulation(NMES) for the treatment of Diabetic Peripheral Neuropathy. A Randomised Controlled Trial	No						05/12/2018							
18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura	No		28			02/03/2018	06/12/2018	11/06/2018		03/01/2019				
18/LO/1187	240011	(A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy)	No					13/04/2018	25/07/2018			24/04/2018			D - Sponsor Delays	Sponsor
															G - No patients consented	
															H - Contracting delays	
18/NS/0093	237699	Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation	Yes	26/11/2018	13	48	61	17/07/2018	26/09/2018			09/10/2018		09/10/2018		
17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dyskinesia Study	Yes	28/08/2018	0	18	18	14/06/2018	10/08/2018			10/08/2018		16/08/2018		
17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	No		62			20/06/2018	20/06/2018	15/01/2018	16/08/2018	21/08/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-Chek® Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPod® in Patients with Type 1 Diabetes	No					12/06/2018	12/06/2018						A - Permissions delayed/denied	Neither
18/SW/0039	229163	Induction of labour for predicted macrosomia	No		14			29/06/2018	03/10/2018	20/03/2018	17/10/2018	17/10/2018		04/12/2018	G - No patients consented	Neither
18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission	No		45			20/06/2018	02/07/2018	12/06/2018	13/08/2018	16/08/2018		17/09/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/LO/0866	224730	Prevention of hypertensive injury to the brain by intensive treatment after intracerebral haemorrhage: a pilot randomised trial of home telemetry-guided treatment	No					13/07/2018	14/11/2018							
17/SS/0105	209066	Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischaemic stroke with proven acute symptomatic occlusion	No					15/06/2018	27/09/2018						D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/1289	245746	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.	Yes	28/11/2018	90	41	131	19/07/2018	20/07/2018	05/09/2018	18/10/2018	18/10/2018		26/11/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	Yes	19/10/2018	112	11	123	26/07/2018	18/06/2018	11/07/2018		08/10/2018			D - Sponsor Delays	Sponsor
18/LO/1882	25303	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant	No						26/11/2018							
18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 – TRial of erYaspase in pancreatic CAncer	No					06/07/2018	31/07/2018	22/08/2018	06/07/2018				J - Other	Neither
18/ES/0071	241904	A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide	No					22/06/2018	28/09/2018						D - Sponsor Delays	Sponsor

															H - Contracting delays	
17/LO/1018	224051	An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies	No		72			01/08/2018	02/10/2018	06/09/2018		13/12/2018		19/12/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0330	236942	A pragmatic, multi-centre, three-armed randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment	No		30			31/07/2018	21/08/2018	25/05/2018	20/09/2018	20/09/2018			E - Staff availability issues	NHS Provid
18/EE/0260	230833	BN40031- CREAD Open Label Extension Study	Yes	18/12/2018	55	27	82	18/09/2017	27/09/2018		21/11/2018	21/11/2018		22/11/2018	D - Sponsor Delays	Sponsor
17/WM/0117	223480	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	No					10/07/2018	12/12/2018							
16/lo/1567	242092	A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma	No					16/01/2018	12/10/2018		09/02/2018				D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/WA/0276	246112	Randomised Double-Blind, Placebo-Controlled (within dose groups) and Active Controlled (Eplerenone group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients with Diabetic Nephropathy	No					03/09/2018	03/09/2018	26/10/2018					D - Sponsor Delays	Sponsor
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	No		19			12/03/2018	23/11/2018		05/12/2018	12/12/2018		12/12/2018		
18/NS/0100	236463	Hand Osteoarthritis: Investigating Pain Effects in a Randomised Placebo-Controlled Feasibility Study of Estrogen-Containing Therapy	No					05/09/2018	14/11/2018							
18/YH/0136	214921	A Multi-Centre, Pilot, Prospective, Clinical Investigation of DermaRep™ Device in the treatment of Venous Leg Ulcers.	No					21/09/2018	26/10/2018	20/08/2018						
16/LO/0422	198606	A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer	No					09/10/2018	25/10/2018	23/05/2016						
18/LO/1911	252871	Pilot study of brain Magnetic Resonance Imaging (MRI) scans to assess bleeding risk in children with immune thrombocytopenia (ITP-low platelet count).	No		10				20/11/2018	16/11/2018	30/11/2018	30/11/2018				
17/NE/0061	215780	Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke - A Randomised Clinical Trial of Low-Dose Colchicine for Secondary Prevention After Stroke	No					08/02/2018	15/11/2018							
18/EM/0256	248467	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction	No					30/08/2018	26/11/2018							
18/LO/1558	248946	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)	No					15/06/2018	11/10/2018						D - Sponsor Delays	Sponsor
18/SC/0444	249450	A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response - CORRECT DOCUMAS REF: 18HH4719 (deleted in error)	Yes	22/11/2018	75	1	76		07/09/2018	25/09/2018		21/11/2018		21/11/2018	D - Sponsor Delays	Sponsor

17/LO/1808	231108	An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy	No					17/10/2018	17/10/2018	18/12/2017							D - Sponsor Delays	Sponsor
																	H - Contracting delays	
18/EE/0300	236285	PROMPT: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer	No					26/10/2018	08/11/2018	19/10/2018								
17/LO/1875	219487	An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse	No					26/09/2018	30/10/2018	08/01/2018								
18/LO/1258	248312	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis	No					02/11/2018	12/11/2018									
18/SO/0384	245537	A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of intravenous boosting with malaria vaccine candidates ChAd63 and MVA encoding ME-TRAP	No		23			07/11/2018	07/11/2018	01/11/2018	30/11/2018	30/11/2018		03/12/2018				
18/LO/2023	253130	A double-blind, randomised, placebo controlled, adaptive design study of the efficacy, safety and pharmacokinetics of NT-814 in female subjects with moderate to severe vasomotor symptoms associated with the menopause	No					13/11/2018	14/11/2018	18/01/2019								
18/WA/0385	254760	A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6- Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	No					21/11/2018	21/11/2018									
18/SC/0591	250421	A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H)	No					08/06/2018	22/11/2018				27/07/2018					
18/LO/1199	241759	Study to compare once-daily Extended Release tacrolimus Versus twice-daily Immediate Release Tacrolimus following renal allograft failure to Reduce the risk of Allo-sensitisation (EVITRA Trial)	Yes	14/11/2018	36	19	55	07/08/2018	20/09/2018	13/08/2018	27/03/2018	26/10/2018						
18/LO/1176	234823	PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODRROMAL TO MILD ALZHEIMER'S DISEASE	No		70			09/04/2018	11/07/2018	21/08/2018		19/09/2018					D - Sponsor Delays	Sponsor
																	G - No patients consented	
18/LO/0900	154432	WithHolding Enteral feeds Around packed red cell Transfusion to prevent necrotising enterocolitis in preterm neonates: a multi-centre, electronic patient record (EPR), randomised controlled point-of-care pilot trial	Yes	13/11/2018	23	41	64	25/04/2018	10/09/2018	06/07/2018	03/10/2018	03/10/2018		12/11/2018				
18/LO/1549	247067	A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown primary - CUPem	No						12/12/2018	15/11/2018								
18/LO/0165	224726	Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study	No					02/11/2018	05/11/2018	09/05/2018	02/11/2018							
17/EE/0382	220851	Predicting Outcomes From Crohn's Disease Using a Molecular Biomarker (PROFILE) Trial.	No		40			02/01/2018	15/06/2018		12/07/2018	25/07/2018		27/07/2018			G - No patients consented	Neither
18/SC/0055	239091	Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage	Yes	06/11/2018	17	39	56	10/01/2018	11/09/2018	05/03/2018	28/09/2018	28/09/2018		06/11/2018				



18/LO/1610	239718	Pilot study assessing the efficacy of Oxaliplatin based Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of colorectal peritoneal metastases deemed not suitable for cytoreduction and heated intraperitoneal chemotherapy.	No		18				08/11/2018			26/11/2018					
18/LO/0797	240879	A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma.	No						18/01/2018	10/06/2018	02/10/2018					D - Sponsor Delays	Sponsor
18/EM/0245	242737	Phase I study of High Intensity Focused Ultrasound (HIFU) in Early Rectal Cancer	No		35				28/08/2018	16/11/2018	01/11/2018		21/12/2018				
18/EM/0244	243585	A Phase II feasibility study of High Intensity Focused Ultrasound (HIFU) in late stage pelvic cancer	No						28/08/2018	16/11/2018	01/11/2018						
18/LO/0012	225166	Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adults with Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR).	No						15/02/2018	29/03/2018	08/03/2018			Sponsor declined site con	C - Closed by sponsor	Sponsor	
16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial	No		28				14/03/2018	10/12/2018	18/08/2017	21/11/2018	07/01/2019				
18/LO/0518	237346	A phase 2/3, multicentre, open-label, multi-cohort, two-part study evaluating the pharmacokinetics, safety and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) administered with a background regimen in HIV-1 infected, treatment experienced, virologically suppressed paediatric subjects	No						04/04/2018	17/10/2018	25/07/2018					D - Sponsor Delays	Sponsor
																H - Contracting delays	
18/LO/0565	241439	Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)	Yes	26/11/2018	160	20	180	12/04/2018	30/05/2018	30/07/2018		06/11/2018				D - Sponsor Delays	Sponsor
																H - Contracting delays	
18/LO/0798	237827	DNAe Diagnostic Evaluation Study	No		81				04/06/2018	14/06/2018			03/09/2018			D - Sponsor Delays	Sponsor
																G - No patients consented	
18/LO/1203	242451	ORBITA-2: A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina (Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina 2)	No							31/08/2018						A - Permissions delayed/denied	Neither
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Yes	11/12/2018	113	35	148	04/05/2018	16/07/2018	13/07/2018	01/11/2018	06/11/2018				D - Sponsor Delays	Sponsor
17/SC/0244	226900	A randomised, parallel-group, double-blind, double-dummy, active-controlled, multicentre study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	Yes	16/08/2018	49	41	90	09/05/2018	18/05/2018	27/07/2017	26/06/2018	06/07/2018		10/07/2018		D - Sponsor Delays	Sponsor
																G - No patients consented	
																H - Contracting delays	
18/LO/1070	174513	Improving the safety of oral immunotherapy for cow's milk allergy (The SOCMA Study)	Yes	15/08/2018	1	27	28	23/05/2018	18/07/2018	18/07/2018	19/07/2018	19/07/2018		19/07/2018			
18/YH/0223	243476	Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care	No		126				07/06/2018	12/07/2018	09/07/2018	14/11/2018	15/11/2018			D - Sponsor Delays	Sponsor
																H - Contracting delays	
18/LO/1317	250312	Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study	Yes	26/10/2018	11	10	21	03/07/2018	05/10/2018	20/08/2018	16/10/2018	16/10/2018		22/10/2018			

18/NI/0129	218623	Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients.	No		19			03/07/2018	15/11/2018	17/10/2018		04/12/2018				
18/LO/1400	250545	A prospective study to assess the efficacy and safety of the BlueWind RENOVA iStim™ system for the treatment of patients diagnosed with overactive bladder	No					18/07/2018	11/10/2018						D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT™  G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Yes	28/11/2018	4	23	27	07/08/2018	01/11/2018	30/03/2017	01/11/2018	05/11/2018				
18/WA/0161	238902	An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N.	No		92			10/09/2018	10/09/2018		10/09/2018	11/12/2018			A - Permissions delayed/denied	Neither
															G - No patients consented	
18/SC/0242	238151	A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.	No					03/10/2018	05/10/2018						D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallelgroup, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost-effectiveness trial with internal pilot	No					12/10/2018	20/12/2018							
18/EM/0311	254008	A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD)	No		6			11/10/2018	14/12/2018	14/12/2018		20/12/2018				
18/WA/0239	243333	Delivering the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis	No					05/12/2018	11/12/2018							